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Abstract
Aims
1. To explain why gene correction technology is a useful tool for studying chronic/
latent viral infections.
2. To explain how gene editing technology may facilitate or restrict virus replication and
impact on future therapy.
3. To cite specific examples of how gene correction technology is being applied to target
specific viruses, including HIV, hepatitis B virus (HBV), herpes simplex virus (HSV),
and other viruses.
Methodology
We attempted to identify all scientific publications including basic science, translation
research, and any clinical trials involving DNA correction technology [zinc finger
endonuclease (ZFN), transcription activator-like endonucleases (TALENs), and
CRISPR/Cas-based systems] and persistent viral infections [including but not limited to
HIV, hepatitis B, C, and D viruses, herpes viruses, cytomegalovirus, Epstein–Barr virus
(EBV), human papillomavirus (HPV), measles virus, and varicella-zoster virus]
published on or before December 31, 2015. We conducted searches of MEDLINE,
Cochrane Central Register, and EMBASE. The identified papers have been summarized
and organized into relevant sections within the chapter.
Conclusion
Sequence-specific DNA endonucleases target and destroy DNA viruses, with early work
describing the use of ZFNs, TALENs, or a third type of endonuclease, called a homing
endonuclease (HE), to target HBV, HPV, and HSV-1 with varying degrees of success.
The new CRISPR/Cas9 systems do not allow virologists to screen for host genes that
affect the replication of pathogenic human viruses but to derive human cell lines that
are genetically engineered to either facilitate or suppress viral replication. Scientists now
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widely use adeno-associated virus (AAV)-based vectors to directly target chronic
viruses that infect discrete organs/tissues in the human body, such as HBV and HSV,
although the safety of such delivery system is still a concern. The eventual goal is to
eradicate or to disable the entire population of latent viral DNA genomes within the
infected cells, resulting in permanent cure for these viral infections, which remains
elusive until now.
Keywords: antiviral gene therapy, CRISPR/Cas, gene editing, sequence-specific DNA
cleavage, TALENs, zinc finger
1. Introduction
Sequence-specific DNA endonucleases were first identified in the 1960s as enzymes that
restrict the ability of DNA bacteriophage to grow in particular bacterial isolates or species.
However, it was many years later that the DNA editing technology for selective modification
of large viral or cellular DNA genomes was developed with the discovery of zinc finger
endonuclease (ZFN) [1]. It was originally developed as an artificial restriction endonuclease
to replace or complement restriction enzymes, and the engineered nucleases have become a
versatile and indispensable tool in research as well as in biotechnology. However, each zinc
finger is not necessarily highly specific for the 3-bp target that it is designed to bind and zinc
fingers specific for all possible 3-bp target sequences have not yet been derived [2].
To address some of the deficiencies of ZFN, transcription activator-like endonucleases
(TALENs) were developed based on a distinct modular DNA-binding motif. TALENs are
made up of four ~34 amino acid domains derived from a DNA-binding protein found in the
pathogenic plant bacterium Xanthomonas, which each recognizes a single DNA base pair with
higher specificity [3, 4]. Although being more specific than ZFNs, TALENs require a rather
laborious exercise in genetic engineering and are quite large, thus limiting the ability to express
TALENs using viral vectors.
The newly developed CRISPR/Cas-based systems, or RNA-guided engineered nucleases
(RGENs), unlike ZFNs and TALENs that use protein motifs for DNA sequence recognition,
depend on RNA-DNA recognition. These are both highly specific and allow facile retargeting
to new genomic loci [5, 6] and may be superseding the two older technologies. A key step
forward in making the CRISPR/Cas9 system more user-friendly is by demonstrating that the
crRNA and tracrRNA could be linked by an artificial loop sequence to generate a fully
functional small guided RNA (sgRNA) [5, 6].
To date, the ever-increasing list of organisms with genomes that have been modified success‐
fully using engineered nucleases includes mosquitoes, crickets, silkworms, pigs, cows, rabbits,
and nonhuman primates, among others [7, 8]. The ability to genetically manipulate human
pluripotent stem cells and somatic cells using engineered nucleases opens new opportunities
to develop novel therapies for patients with various genetic and acquired diseases. Genetic
defect correction is now possible in cultured cells from patients with a number of genetic
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diseases, including sickle cell disease [9], cystic fibrosis [10], Down syndrome [11], Duchenne
muscular dystrophy [12], α1-antitrypsin deficiency [13], dystrophic epidermolysis bullosa
[14], chronic granulomatous disease [15], and infectious diseases, particularly persistent viral
infections that were among the most attractive targets in both ex vivo and in vivo studies,
which will be discussed in the rest of the chapter. Despite all these promising advances, we
should also be aware that these DNA editing technologies have been shown to cut at off-target
sites with mutagenic consequences. Therefore, issues such as efficacy, specificity, and delivery
are likely to drive selection of reagents for particular purposes. Human therapeutic applica‐
tions of these technologies will ultimately depend on risk-versus-benefit analysis [8].
2. Main text
2.1. Why is DNA editing technology important in chronic viral disease research?
Chronic viral infection underlies a wide variety of medically important diseases that either
follow directly from primary infection or may require months, years, or even decades to
develop. Diseases caused by persistent virus infections include AIDS, AIDS-related complexes,
chronic hepatitis, subacute sclerosing panencephalitis (chronic measles encephalitis), chronic
papovavirus encephalitis (progressive multifocal leukoencephalopathy), several herpes virus–
induced diseases, and some neoplasias (see Table 1). Pathogens with worldwide impact, such
as HIV, hepatitis B virus (HBV), and a number of herpes viruses remain uncontrolled. The
pathogenic mechanisms by which these viruses cause diseases include disorders of biochem‐
ical, cellular, immune, and physiologic processes. The chronic nature of these infections limits
the number of antiviral options and increases the risk of developing drug-resistant strains in
the host. Some recent studies suggest that chronic viral infection also contributes to certain
cancers as well as to diabetes and atherosclerosis. Ongoing studies are rapidly advancing our
understanding of many persistent infections. Viruses have evolved a wide variety of strategies
by which they maintain long-term infection of populations, individuals, and tissue cultures.
Most of our current understanding of the host immunity and viral virulence are from studies
on the progression of acute infection. When a virus enters the host, there is an initial nonequi‐
librium phase of acute infection, in which viral and immune strategies compete for dominance.
A transition point will be reached in a survivor, at which the infection either is cleared or
becomes chronic. This transition point may be reached very early in infection for viruses that
can establish a latent infection, in which case the infection is permanent regardless of the course
of acute infection. If recovery occurs, the immune system must reset by clearing the antigen
and reestablishing immune homeostasis. If the balance shifts toward chronic infection, a new
set of viral and host strategies interact to define a metastable equilibrium in which viral
replication is held in check, but the virus is not cleared [16].
Whereas acute viral infection represents a nonequilibrium process, chronic viral infection is a
process in dynamic and metastable equilibrium. During acute infection, both the host and the
virus change continuously until infection is resolved, kills the host, or becomes chronic. Certain
genes in a virus or in the immune system function during acute but not chronic infection. The
failure of these immune system genes to function effectively or the overly effective evasion of
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immunity by the virus may eventually lead to multiorgan failure and death. In contrast, during
chronic infection, viral and host genes balance each other [16]. The mechanisms of viral
persistence despite the impressive immune armamentarium of the host, without causing overt
disease, remain unclear, although the events leading to the establishment of chronicity were
described.
Two events are fundamental to the establishment of chronic viral infection. First, the virus
must evade sterilizing immunity (the complete elimination of a virus). Second, the immune
system must adjust to the continuous presence of viral antigen-driven inflammatory responses
to limit viral replication to an acceptable level without untoward damage to permanently
infected tissues. If the immune system cannot eliminate the virus, unrestrained immune attack
on virus antigen-bearing cells causes tissue injury. Thus, down-regulation of inflammation
during chronic viral infections can result in decreased tissue damage, at least for noncytopathic
viruses. Immunopathology can be severe in human chronic infections caused by HBV and
hepatitis C virus (HCV) [46], which may remain noncytopathic for many decades initially. It
is important to realize that viruses which rely on a living but chronically infected host for their
own survival must carefully avoid mechanisms that overwhelm immunity and kill their hosts.
Viruses have evolved highly effective strategies for establishing chronic infection despite the
presence of an active host antiviral immune response. There are three general strategies for
chronic viral infection: continuous replication, latency and reactivation, and invasion of the
genome followed by vertical spread from generation to generation. Individual viruses usually
rely mostly on one strategy, but viruses can use more than one mechanism. For example, HIV
effectively uses both continuous replication and establishment of latency [47–49], a dangerous
combination. The differences between these strategies have profound implications for
designing new ways to prevent or control harmful chronic viral infections.
The mechanisms of the viral persistence have not been completely understood, and some
common factors are known [50]. Immune modulation is one of them. Many of these viruses
managed to avoid the specific and nonspecific immune defenses in several different ways.
These include (1) limitation of recognition molecules on infected cells; (2) altered lymphocyte
and macrophage functions, including the modified production of cytokines and general
immunosuppression [e.g., HIV-1 and -2, Epstein–Barr virus (EBV), and HBV]; (3) infection in
immunologically privileged anatomic sites [e.g., herpes simplex virus (HSV) and VZV in
central nervous system]; (4) compromised nonspecific defenses (e.g., suppress interferon
production); and (5) immune tolerance (e.g., HBV).
Another common mechanism is the modulation of viral gene expression. Such examples
include (1) down-regulation of some viral genes by viral or cellular regulatory gene products
[e.g., HIV and human papillomaviruses (HPVs)], (2) specific latency-associated proteins (e.g.,
EBNA-1), and (3) synthesis of latency-associated transcripts (LATs; e.g., HSV-1 and -2) as well
as viral variants (e.g., HIV and measles) [50].
Developing a successful cure for persistent or chronic viral infections remains a major
challenge due to their ability to evade/suppress the immune system and their ability to
incorporate viral sequences into the host genome and long inactive latent phases, which makes
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targeting of active biological activities nearly impossible. However, recent concerted effort and
improvement of drug design, leading to multiple new drugs that successful cure HCV,
demonstrate that the complete clearance of chronic viral infections is an attainable goal. A
particularly tantalizing application of programmable nucleases is the potential to directly
correct genetic mutations in affected tissues and cells to treat diseases that are refractory to
traditional therapies. A number of approaches targeting specific disease-causing viral infec‐
tions will be discussed in the following sections.
Disease during chronic infection
Virus,
primary
nucleic acid,
estimated percent
of humans
infected
Major site of
persistence
(organ or cell)
Acute
infection
examples
Within
normal
hosts
Within immuno
compromised hosts
References
Hepatitis B virus
(HBV), DNA, 350
million, −5%
Hepatocytes Hepatitis Cirrhosis,
hepatocellular
carcinoma
Same diseases McGovern [17];
Rehermann and
Nascimbeni
[18]
Hepatitis C virus
(HCV), RNA, 170
million, −2.5%
Hepatocytes Hepatitis Cirrhosis,
hepatocellular
carcinoma
Same diseases Rehermann and
Nascimbeni
[18]; Lemon et
al. [19]
Human
immunodeciency
virus (HIV-1 and
HIV-2), RNA, 33
million, −0.5%
CD4+ T cells,
monocyte/
macrophages
Acute febrile
illness
AIDS AIDS UNAIDS [20];
Kuritzkes and
Walter [21]
Hepatitis D virus
(HDV), RNA, 15
million, −0.2%
Hepatocytes Unknown Exacerbation of
chronic HBV
infection
Unknown Taylor et al.
[22]
Human T cell
leukemia virus type 1
(HTLV1), RNA, 10–20
million, −0.2%
T cells Unknown Adult T cell
leukemia (2–6% of
carriers), tropical
spastic para-
paresis,
myelopathy,
uveitis, dermatitis
Unknown Matsuoka and
Jeang [23];
Lairmore and
Franchini [24]
Xenotropic murine
leukemia virus-related
Prostate Unknown Prostate cancer? Unknown Urisman et al.
[25]; Dong et al.
[26]
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Disease during chronic infection
Virus,
primary
nucleic acid,
estimated percent
of humans
infected
Major site of
persistence
(organ or cell)
Acute
infection
examples
Within
normal
hosts
Within immuno
compromised hosts
References
virus (XMLV), RNA,
unknown
Rubella virus,
German measles,
RNA,
rare
CNS Rubella,
arthritis
Progressive
rubella
panencephalitis
Unknown Hobman and
Chantler [27]
Parvovirus B19,
DNA, rare
Bone marrow
erythroid
progenitors
Fifth disease,
arthritis
Aplastic crisis in
hemolytic anemia,
hydrops fetalis,
chronic bone
marrow de ciency
Red cell aplasia Berns and
Parrish [28];
Norja et al. [29]
Human
papillomavirus,
DNA, <5%
Epithelial skin
cells
Unknown Papilloma,
cervical and other
mucosal
carcinomas
Increased severity
and incidence of same
diseases
Leggatt and
Frazer [30];
Howley and
Lowy [31]
Measles virus, RNA,
rare
Neurons and
supporting cells in
CNS
Measles Subacute
sclerosing
panencephalitis,
measles inclusion
body encephalitis
Unknown Griffin [32]
Coxsackie, RNA, rare Myocardial cells Hand foot and
mouth disease,
herpangina
Myocarditis Unknown Chapman and
Kim[33];
Whitton and
Feuer [34]
Human herpes
virus 6 (HHV-6),
DNA, >90%
Lymphocytes? Roseola Unknown Meningoencephalitis,
secondary infections,
immunomodulatory?
Straus[35];
Yamanishi et al.
[36]
Varicella zoster virus
(VZV), DNA, >90%
Sensory ganglia
neurons and/or
satellite cells,
lymphocytes
Chicken pox Herpes zoster Disseminated disease,
hepatitis, pneumonitis
Zerboni and
Arvin [37];
Straus [38]
Cytomegalovirus
(CMV), DNA, 80%–
90%
Myelomonocytic
cells
Mononucleosis Rare Disseminated disease,
vasculitis, pneumonitis,
retinitis, hepatitis,
Mocarski et al.
[39]
Modern Tools for Genetic Engineering72
Disease during chronic infection
Virus,
primary
nucleic acid,
estimated percent
of humans
infected
Major site of
persistence
(organ or cell)
Acute
infection
examples
Within
normal
hosts
Within immuno
compromised hosts
References
gastroenteritis,
meningoencephalitis
Epstein–Barr virus
(EBV), DNA, 80–90%
Pharyngeal
epithelial cells, B
cells
Mononucleosis Burkitt’s
lymphoma,
nasopharyngeal
carcinoma, non-
Hodgkin’s
lymphoma
CNS lymphomas, oral
hairy leukoplakia,
lymphoproliferative
disease
Rickinson and
Kieff [40];
Straus [38];
Kieff and
Rickinson [41]
Polyomavirus BK,
DNA, 72–98%
Kidney Unknown Unknown Hemorrhagic cystitis
(post bone marrow
transplantation),
nephropathy (post
kidney transplantation)
Zur [42]
Polyomavirus JC,
DNA, 72–98%
Kidney, CNS Unknown Unknown Progressive multifocal
leukoencephalopathy
Zur [42]
Herpes simplex
type 1 (HSV-1),
DNA, 50–70%
Sensory ganglia
neurons
Pharyngitis,
encephalitis,
keratitis
Cold sores,
encephalitis,
keratitis
Increased severity of
same diseases,
pneumonitis, hepatitis
Straus [38]
Adenovirus, DNA,
up to 80%
Adenoids, tonsils,
lymphocytes
Upper
respiratory
infection,
gastroenteritis
Unknown Enteritis, hemorrhagic
cystitis, pneumonitis,
hepatitis, others
Garnett et al.
[43]; Wold and
Horwitz [44]
Herpes simplex
type 2 (HSV-2),
DNA, 20–50%
Sensory ganglia
neurons
Genital herpes Genital herpes,
encephalitis
Increased severity of
same diseases
Straus [38]
Kaposi’s
sarcoma
herpes
virus (KSHV)
or human
herpes virus
8, DNA, 2–60%
Endothelial cells,
B cells
Unknown Castleman’s
disease, Kaposi’s
sarcoma
Kaposi’s sarcoma,
primary effusion
lymphoma
Ganem [45]
Table 1. List of known human pathogenic chronic viral infections and their respective prevalence and clinical disease
[16].
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2.2. Defining the cellular factors that facilitate or restrict virus replication
Using sequence-specific DNA endonucleases to target and destroy DNA viruses had been
attempted almost as soon as the technology was invented [51], with earlier work describing
the use of ZFNs, TALENs, or an earlier HE, to target HBV, HPV, and HSV-1.
The newer DNA editing systems not only impact virology by allowing researchers to screen
for human genes that affect the replication of pathogenic human viruses and are extremely
useful in generating human cell lines that lack gene products that may facilitate or restrict
specific virus replication. Adeno-associated virus (AAV)-based vectors offer the possibility of
directly targeting DNA viruses that infect specific organs or tissues in the human body (e.g.,
HSV and HBV) to target and destroy the entire population of viral DNA genomes. Safety
concerns, such as off-target genomic mutations, of such delivery system remains [52].
Viruses have very compact genomes and therefore rely on the host cell for many activities
required to support their replication cycle. Ironically, viruses as pathogens put selective
pressure on their host organisms, thus selecting for cellular restriction factors that can limit its
own level of viral replication. One of the best studied viruses in this context is HIV, which
requires a wide range of human cofactors for replication in CD4+ T cells, several of which are
lacking in other mammalian species, such as in mice. HIV is targeted by a wide range of human
restriction factors and dedicates a substantial portion of its coding capacity to the neutraliza‐
tion of these restriction factors. For example, the Vif protein blocks the activity of the host
APOBEC3 family of restriction factors, which otherwise interfere with the production of the
HIV-1 provirus, whereas the HIV-1 Vpu protein neutralizes the cellular restriction factor
tetherin, which blocks the release of progeny virions [53].
The identity of cellular factors that either facilitate or restrict viral replication is central to the
search for novel targets for antiviral drug development. Researchers have been using RNA
interference (RNAi) libraries to knock down the expression of human genes systematically to
identify factors required for virus replication. Although this approach has led to some
interesting insights, it is also clear that RNAi screens for viral cofactors in different laboratories
have often led to very different lists of cellular proteins with this potential activity. This may
be due to the use of different cell systems, different assays for viral replication, different RNAi
reagents, and sometimes incomplete knockdown of target gene expression. As a result, most
of the viral cofactors and restriction factors identified so far have required confirmation using
biochemical approaches (e.g., by identification of cellular factors that specifically bind to a viral
protein) or genetic approaches (e.g., by complementation of a human and/or animal cell line
that lacks a particular cofactor or restriction factor) [52, 53].
RGEN systems appear highly suitable for use in screens for viral cofactors or restriction factors;
indeed, several screens for cellular factors involved in cell transformation have been published
[54–56]. This could now be extended to analysis of the replicative potential of viruses in a 96-
or 384-well plate format, possibly in the form of comprehensive CRISPR/Cas9-generated
libraries of cellular clones available for specific human cell lines. Each of these lines will lack
a functioning gene that is dispensable for cell viability in a tissue culture setting. These clones
should allow the reproducible and almost complete identification of cellular factors that either
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help or hinder virus replication in that human cell line in vitro. Factors required for human
cell viability would be missed, but it seems likely that almost all host innate immune factors
involved in restricting virus replication would not be essential. Essential factors required for
host cell viability must also be essential for virus replication and clearly would not provide
potential targets for antiviral drug development. A summary of studies using DNA editing
technology to define the host factors that facilitate or restrict virus replication is listed in
Table 2.
Defining the host factors that facilitate or restrict virus replication
Virus Human
disease
Type Host
factors
studied
Cell/
animal/
human
study
Delivery
method
Reference
Cytomeg
alovirus
(CMV)
Disseminated
disease,
vasculitis,
pneumonitis,
retinitis,
hepatitis,
gastroenteritis,
meningo
encephalitis
TALEN Glucoc
orticoid
receptor
(GR)
gene
CD8 + T
cells
Electroporation Menger et al. [57]
Hepatitis
C virus
(HCV)
Cirrhosis,
hepatocellular
carcinoma
TALEN DGAT1 Huh7.5 cells Transfection Sung et al. [58]
CRISPR CLDN1,
OCLN
and
CD81
Huh7.5 cells Ren et al. [59]
CRISPR ISG15 Huh7 cells Transfection Domingues et al. [60]
Herpes
simplex
type 1
(HSV-1)
Core sores,
encephalitis,
pneumonitis,
hepatitis
CRISPR IFI16 U2OS cells Transfection Johnson et al. [61]
CRISPR LULL1 HeLa cells Transfection Turner et al. [62]
Human
immuno
deficiency
virus
AIDS ZFN CCR5 CD4 + T
cells,
human
AAV Perez et al. [63], Tebas et al. [64]
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Defining the host factors that facilitate or restrict virus replication
Virus Human
disease
Type Host
factors
studied
Cell/
animal/
human
study
Delivery
method
Reference
(HIV-1)
CRISPR CCR5 CD4 + T cells Ad5F35
adenoviral
vector
Li et al. [65]
Kaposi’s
sarcoma
herpes
virus
(KSHV) or
human
herpes
virus 8
Kaposi’s
sarcoma,
primary
effusion
lymphoma
CRISPR ORF45,
RSK
SLK-iBAC
cells
Lentiviral
delivery
method
Avey et al. [66]
Human
papillo
mavirus
Papilloma,
cervical
and other
mucosal
carcinoma
TALEN E6, E7
ORFs
SiHa or
HeLa cells,
Mice
Transfection Hu et al. [67]
CRISPR E6, E7
ORFs
HeLa
cells
Transfection Kennedy et al. [68]
Table 2. Summary of studies using DNA editing technology to define the host factors that facilitate or restrict virus
replication.
2.3. Using engineered nucleases for gene therapy applications in specific viral pathogens
2.3.1. Human immunodeficiency virus (HIV)
In the last two decades, the availability of highly active antiretroviral therapy (HAART)
capable of reducing HIV replication to undetectable level and prolonged survival has greatly
improved the prognosis of infected patients. However, HIV-1 persists as a latent infection in
a small number of resting CD4+ memory T cells [47]. In these long-lived cells, intact integrated
HIV-1 proviruses persist in a transcriptionally silent state that is refractory to both drugs and
host immune responses. However, these memory T cells can be reactivated by an appropriate
recall antigen, resulting in the induction of a productive viral replication cycle [47, 49]. If this
occurs after drug treatment has been stopped, HIV-1 will rapidly spread through the available
CD4+ T cells and rekindle the same level of virus replication that was seen before antiviral drug
treatment. Other disadvantages of such long-term therapy include limitations including high
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cost, patient compliance and side effects of long-term therapy, as well as emergence of drug
resistance [84]. Therefore, there is a need to develop a more effective “cure” for HIV infection.
The approaches to purge the pool of latently infected cells have focused on two strategies.
Some have attempted to activate latent HIV-1 proviruses using drugs, including histone
deacetylase inhibitors and protein kinase C agonists [85]. However, so far, this strategy has
not been proven able to activate HIV-1 in a high percentage of latently infected cells.
An alternative strategy would be to directly target and destroy latent proviruses using HIV-1-
specific CRISPR/Cas combinations. Early attempts have shown that this is feasible and that
latent proviruses can be excised from the host cell genome, and then destroyed, by cleavage
in the HIV-1 long terminal repeat regions [86, 87]. In principle, the HIV-1 provirus is a perfect
target for CRISPR/Cas, as there is only a single proviral copy in the infected cell, and in the
presence of antiviral drugs, no spread of the virus is possible. The problem, however, is that
latently HIV-1-infected T cells are scattered throughout the body and infecting all of these
seems currently to be an insurmountable problem, especially as T cells are poor targets for
AAV infection. This contrasts with HBV, HSV, and HPV, all of which are tightly localized in
known tissues in the body that can be readily targeted by AAV [52]. Therefore, in the absence
of novel vector delivery systems that can target latently HIV-1-infected cells throughout the
body, HIV-1 is likely to remain a technically challenging target for elimination by CRISPR/Cas
in vivo.
CCR5, which encodes a coreceptor for HIV entry [88, 89], has been a popular target for
developing a new generation of HIV therapy for several reasons. First, its disruption seemed
likely to increase the survival of CD4T cells; persons homozygous for a naturally occurring 32-
bp deletion (delta32/delta32) in CCR5 are known to be resistant to HIV infection [90]. CD4 T
cells from such persons are highly resistant to infection in vitro [91]. Persons who are hetero‐
zygous for CCR5 delta32 and HIV infection have slower progression to full-blown AIDS [92,
93]. The effectiveness of blocking or inhibiting CCR5 with the use of small interfering (siRNA)
and other small-molecule inhibitors has been shown in humans [94]. Finally, there is the
remarkable success story of HIV eradication in the so-called “Berlin Patient”. This HIV-positive
patient with lymphoma, who had been transplanted with bone marrow from a CCR5-Δ32
homozygous donor, became cured with no measurable virus (undetectable HIV RNA and
proviral DNA in the blood, bone marrow, and rectal mucosa) even 5 years after transplanta‐
tion, showing the potential benefits of CCR5 disruption [95, 96]. Although the mechanism
responsible for the apparent cure associated with this procedure remains to be established,
acquired CCR5 deficiency is one possibility [97]. Due to the low frequency of CCR5-Δ32
homozygotes in the general population and the difficulties of identifying suitable donors,
alternative methods to artificially disrupt CCR5 are being sought [65]; in particular, gene
editing methods have attracted a lot of attention as a potential therapy for HIV, as they allow
permanent disruption of the selected gene(s).
This approach had recently led to a phase I clinical study published in the New England Journal
of Medicine [64]. The researchers enrolled 12 patients in an open-label, nonrandomized,
uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells. Six of these 12
patients underwent an interruption in antiretroviral treatment 4 weeks after the infusion of 10
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billion autologous CD4 T cells. Between 11% and 28% of these CD4 T cells were genetically
modified by ZFN. The primary outcome was safety in terms of treatment-related adverse
events. Secondary outcomes included measures of immune reconstitution and HIV resistance.
The only serious adverse event associated with infusion of the ZFN-modified CD4 T cells was
attributed to a transfusion reaction. The median concentration of CCR5-modified CD4 T cells
at 1 week was 250 cells/mm3. This represented approximately 8.8% of circulating peripheral
blood mononuclear cells and 13.9% of circulating CD4 T cells. These modified T cells had an
estimated mean half-life of 48 weeks. During treatment interruption and the resultant viremia,
the decline in circulating CCR5-modified cells (-1.81 cells/day) was significantly less than the
decline in unmodified cells (-7.25 cells/day; p = 0.02; see Figure 1) [64]. HIV RNA became
undetectable in one patient. The blood level of HIV RNA decreased in the majority of the study
subjects. This provides one of the first evidence that CCR5-modified autologous CD4 T-cell
infusions are safe and opens the door for applying DNA editing technologies for treating
human chronic viral diseases, although many obstacles remain.
Figure 1. CCR5-modified CD4 T cells during treatment interruption [64].
2.3.2. Hepatitis B virus (HBV)
HBV remains a major public health problem, with more than 300 million people chronically
infected worldwide [98]. These individuals have an approximately 25% risk of dying from the
consequences of HBV infection, including hepatocellular carcinoma (HCC) and cirrhosis, and
approximately 800,000 individuals are thought to die each year due to HBV. An effective
vaccine for HBV is available, but this is not helpful in individuals with preexisting infection
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and is not fully effective at preventing vertical transmission, compounded by the problem that
it is not given to all children in resource-limited regions timely. HBV polymerase can be
effectively inhibited by nucleoside-based antiviral agents (lamivudine, adefovir, telbivudine,
entecavir, tenofovir), but this does not cure this infection due to the extraordinary stability of
the viral episomal cccDNA intermediate [99], which continue to persist and produce new viral
particles, as soon as the antiviral agents were stopped.
Current research in HBV therapy focuses on finding new targets on the viral life cycle (see
Figure 2) and trying to overcome immune tolerance through immunotherapy, with limited
success. It is clear that a complete “cure” cannot be achieved unless the new therapy is able to
remove or destabilize the HBV cccDNA, and genome editing is one of the most promising
approaches. Some of the challenges that need to be overcome include toxicity, development
of viral resistance, specificity, ensuring therapeutic effect of sufficient duration, and
hepatocyte-targeted delivery. Significant progress has been made to overcome these obstacles.
Figure 2. Replicative cycle of HBV and the respective targets of the current and experimental therapeutic agents (modi‐
fied from Phyo et al. [100]).
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Zimmerman et al. [101] were the first to advance a gene editing approach to countering HBV
replication. The researchers used duck HBV (DHBV) as a model and designed six different
zinc finger proteins (ZFPs) to target the DHBV enhancer sequences, which control the
transcription of the core and surface sequences. Marked reduction in viral pgRNA and total
viral RNA was observed. ZFPs significantly reduced viral core and surface protein production
with no obvious cytotoxicity. As the ZFPs did not cause target DNA mutation or durable
epigenetic changes, this inhibition was not lasting. Later, Cradick et al. [71] also demonstrated
the effectiveness of using ZFNs to specifically cleave HBV episomal DNA. The team engi‐
neered nine pairs of HBV-specific ZFNs and cotransfected each of these ZFN pair plus an HBV
genome target plasmid into a hepatoma cell line. Targeted cleavage of viral DNA was
demonstrated. The cleaved fragments were misrepaired in a manner that could potentially
inactivate HBV. Further, cotransfection with the ZFN pair 6 decreased HBV pregenomic viral
RNA levels by almost 30%. However, it should be noted that the study did not clearly
demonstrate that the HBV cccDNA was modified by the ZFNs.
The X gene is thought to play a major role in the development of HCC [102]. Zhao et al. [103]
designed ZFPs to inhibit the expression of integrated sequences of the X gene. An artificial
transcription factor (ATF) was synthesized to target a sequence in the enhancer I region, which
is upstream of the X promoter. The ATF comprised a DNA-binding domain of a ZFP that was
linked to a KRAB repressor domain. X repression was demonstrated on a luciferase reporter
assay. Another study by Weber et al. [72] aimed to prevent viral reactivation by targeting three
HBV protein-coding sequences with ZFNs in HepAD38 cells, a tet-regulated cell line. AAV
vectors containing sequences encoding the ZFNs were used for gene delivery. Site-specific
mutagenesis with low cytotoxicity was confirmed for two of three engineered ZFNs. Inhibition
of HBV replication and virion production over a period of 14 days could be achieved after a
single treatment with ZFN targeting the viral polymerase gene.
Bloom et al. [73] first applied TALENs to disrupt hepatitis B replication in a cell line and a
mouse model. HBV-specific TALENs were generated, targeting conserved sequences in the
surface, core, and pol open reading frames (ORFs). The TALEN targeting surface and core
ORFs were the most effective. The viral cccDNA were isolated using Hirt’s extraction and
plasmid-safe DNase. T7 endonuclease I assay was used to verify targeted mutation in cultured
cells. The TALEN targeting surface ORF reduced HBsAg by more than 90% and circulating
viral particle equivalents were diminished by approximately 70% by the S and C TALENs.
T7E1 assays and deep sequencing confirmed the targeted disruption. Chen et al. [74] confirmed
the successful targeting and inactivation of HBV genomic sequences by TALENs. The re‐
searchers also showed significant knockdown in markers of viral replication. Interestingly,
when used in combination with interferon-α, synergistic antiviral effects were observed.
Although promising, a limitation of using mice to simulate HBV replication in vivo is that
these animals do not produce HBV cccDNA.
Some key studies employing CRISPR/Cas9 systems recently demonstrated the utility of RGEN
cleavage of HBV DNA [75–78]. Lin et al. [75] designed eight HBV-targeting sgRNAs to target
different conserved regions of the HBV genome. A significant decrease in the production of
viral proteins was observed. Cotransfection with more than one sgRNA-encoding sequence
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augmented antiviral efficacy. This effect was corroborated by an increase in indels at the
targeted sites. However, the efficacy against HBV cccDNA was not evaluated. Seeger and Sohn
[76] investigated the targeted disruption of HBV cccDNA and confirmed the efficient cleavage
of viral sequences with all five of their sgRNA constructs. Approximately eightfold reduction
of HBcAg expression was achieved in HBV-infected HepG2-NTCP cells. The cells were
transduced using recombinant lentiviral vectors. Targeted deletions from single nucleotide up
to 2.3 kb was produced. This demonstrated the potential of CRISPR/Cas to target and excise
host-integrated HBV genomes. Another similar study by Kennedy et al. [77] also showed
suppression of HBV replication by lentiviral vector-delivered Cas9 and sgRNA sequences.
Dong et al. confirmed the efficacy of sgRNA-Cas9 against HBV. In addition, they demonstrated
the disruption of artificial cccDNA in a murine hydrodynamic model [78] that was based on
the use of engineered recombinant cccDNA precursor plasmid (rcccDNA) [104].
These studies suggest that HBV-specific Cas9/sgRNA combinations can block HBV replication
and eliminate the cccDNA pool if they can be effectively delivered to hepatocytes. At the
moment, AAV may be the best carrier for this task, as several AAV serotypes are naturally
hepatotropic and even more highly hepatotropic AAV vectors have recently been isolated by
“shuffling” AAV sequences in vivo [105]. The next step is to examine whether AAV-delivered
Cas9/sgRNA combinations can effectively cure HBV in the humanized, immunodeficient
mouse liver model system.
2.3.3. Herpes simplex virus (HSV)
HSV-1 infects approximately 70% of the U.S. population and about one third of affected
individuals suffer from recurrent, primarily oral, cold sores. HSV-1 most commonly initially
infects the oral mucosal epithelium, leading to a local productive infection, and then undergoes
retrograde transport to the trigeminal ganglia, where it establishes a latent infection in a small
number of sensory neurons, which persists after the initial, productive infection is cleared by
the host immune response [106]. During latency, the HSV-1 DNA genome is maintained as a
nuclear episome, with 1 to ~50 copies per latently infected neuron. At this point, the only region
of the genome that is actively transcribed encodes the LAT, which is processed to give rise to
a single long noncoding RNA of 2.1 kb, as well as eight virally encoded miRNAs, which
together are thought to regulate exit from latency [107]. Because no viral proteins are made,
there is no immune recognition of latently infected cells. Occasionally, one or more latently
infected neuron is activated to produce infectious virions that migrate down the axons of the
reactivating neuron to the original site of infection, where they reestablish a transient produc‐
tive infection that can lead to the formation of cold sores. Although often no more than an
irritation, HSV-1 infections can also lead to serious morbidity and HSV-1 keratitis represents
the most common form of infectious blindness in the West [108]. Infection of the central
nervous system may also cause fatal encephalitis. A closely related virus, HSV-2, which is
found in approximately one fifth of the U.S. population, has a similar replication cycle but
generally is sexually transmitted and infects the genital mucosa. Latency is established in
sensory neurons of the sacral ganglia and reactivation can lead to genital ulcers. Again, serious
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morbidity is rare but does occur in some individuals and neonatal HSV-2 infections acquired
during vaginal delivery can be fatal [106].
Although there are several drugs that can treat productive HSV-1 or -2 infections, generally
by targeting viral DNA synthesis, latent HSV genomes are entirely refractory to current
treatment regimens and it remains impossible to cure these infections. What is clearly needed
is an approach that directly targets HSV-1 or HSV-2 episomal DNA for cleavage and
elimination from latently infected neurons. AAV-delivered HSV-specific engineered
endonucleases appear ideal for this purpose. Aubert et al. [79] introduced DNA double-
stranded breaks in an HSV latency model using the engineered HE HSV1m5, which targets a
sequence in the HSV-1 gene UL19, encoding the viral protein VP5. Coexpression of the 3′-
exonuclease Trex2 with HEs increased the mutagenesis frequencies by up to sixfold. Following
HSV1m5/Trex2 delivery with AAV vectors, the target site within latent HSV genomes was
mutated. There was no detectable cell toxicity. The viral production by latently infected cells
after reactivation was significantly decreased. Prior HSV1m5/Trex2 treatment followed by
exposure to histone deacetylase inhibitors increased mutagenesis frequencies of latent HSV
genomes by another twofold to fivefold. This indicates that chromatin modification may be a
useful adjunct to gene-targeting methods. Using CRISPR/Cas9-mediated genome engineering
to create single- and double-knockout (KO) cell lines, Turner et al. [62] discovered that the
Torsin Activator LULL1 is required for efficient growth of HSV-1, whereas Johnson et al. [61]
reported that the interferon-γ-inducible factor 16 (IFI16) restricts HSV-1 replication by
accumulating the HSV-1 genome and repressing HSV-1 gene expression, and modulates
histone modifications. Given the tight localization of HSV-1 and -2 to the trigeminal and sacral
ganglia, respectively, low level of viral DNA genomes present in these cells, and the ability to
efficiently transduce sensory neurons with AAV8-based vectors, this seems like an ideal viral
candidate for cure using RGENs.
2.3.4. Human papillomavirus (HPV)
HPV infection, although normally innocuous, can also give rise to warts on the skin or genitalia
[31]. Most HPV variants replicate as episomes in the basal epithelial layer of the skin, where
the virus expresses exclusively nonstructural proteins. When the infected precursor epithelial
cell migrates toward the surface of the epidermis and undergoes differentiation into a
keratinocyte, the productive HPV replication cycle is activated leading to the release of
infectious HPV virions (Figure 3) [31].
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Figure 3. HPV penetrating the basal layer and released at the epithelial surface (Medscape [109]).
Although most HPVs are nonpathogenic, there are a small number of high-risk HPV serotypes,
especially HPV-16 and -18, which together cause approximately 70% of all cervical cancers. In
most HPV-induced cancers, the HPV episome is found clonally integrated into the cell genome
in a manner that destroys or deletes the viral E2 gene (E for early) [31]. The role of the E2 protein
is to bind to the HPV origin of replication, where it functions to ensure the distribution of HPV
episomes to both daughter cells after cell division, and E2 also acts to regulate HPV early gene
transcription. One key activity of E2 is to limit the expression of the HPV oncogenes E6 and
E7, and disruption of E2 during integration into the host cell genome can lead to high constit‐
utive levels of E6 and E7 expression [110]. E6 functions to bind and destabilize the p53 tumor
suppressor [111], whereas E7 similarly binds and destabilizes the Rb tumor suppressor [112],
and these two functions play a critical role in the maintenance of HPV-transformed cells.
Cancers associated with HPV infection include cervical carcinoma, which is almost always
HPV positive, as well as a fraction of head and neck (H&N) carcinoma and anal cancer, all of
which are related to sexual transmission of HPV. Novel treatment for chemoresistant HPV-
positive tumors will be important for treating recurrent disease. Of note, almost all HPV-
positive H&N and anal cancers are HPV 16 positive, thus restricting the required sequence
range for engineered endonuclease-based therapy.
Both HPV E6 and E7 proteins play a crucial role in HPV tumorigenesis by blocking the action
of p53 and Rb, respectively [112]. Consistent with this idea, the inactivation of the E6 gene in
the HPV-18-positive cervical carcinoma cell line HeLa or the HPV-16-positive cell line SiHa
using Spy CRISPR/Cas has been found to result in the induction of p53 expression followed
by the expression of downstream targets of this cellular transcription factor, including the CDK
inhibitor p21 and several activators of apoptosis, leading to cell cycle arrest and cell death [68,
82]. Similarly, disruption of the E7 gene using CRISPR/Cas results in the increased expression
of Rb, formation of Rb/E2F heterodimers, and then the induction of cellular genes that induce
senescence and cell death [68, 113]. Mino et al. [81] improved the design of a ZFN-based hybrid
Gene Correction Technology and Its Impact on Viral Research and Therapy
http://dx.doi.org/10.5772/62231
83
nuclease to the single-chain FokI dimer (scFokI) and demonstrated that it inhibited HPV-18
DNA replication in transient replication assays using mammalian cells more efficiently. By
linker-mediated PCR analysis, the researchers confirmed that AZP-scFokI cleaved an HPV-18
ori plasmid around its binding site in mammalian cells. These studies suggest that targeted
endonucleases specific for HPV E6 and/or E7 has the potential to serve as a novel, highly
specific, and effective therapy for chemoresistant HPV-16 induced anal and H&N tumors.
2.3.5. Other viruses
A number of other chronic virus infections are associated with serious human diseases
including EBV, cytomegalovirus, HCV, Kaposi’s sarcoma-associated herpes virus (KSHV),
human T-cell leukemia virus type 1 (HTLV-1), and Merkel cell polyomavirus (MCPyV) (see
Tables 2 and 3). Of these, perhaps the most relevant in relation to DNA editing technology is
EBV. EBV is the etiologic agent of several cancers, including an epithelial cell tumor called
nasopharyngeal carcinoma (NPC), which is highly prevalent in southern China and Southeast
Asia [40, 52]. In NPC cells, EBV is found in a form of viral latency that nevertheless involves
the expression of several viral nonstructural proteins and microRNAs [114]. EBV-positive
NPCs share a number of characteristics with HPV-16-positive H&N cancers, and as in the latter
case, the continued presence and transcription of the viral (in this case, EBV) genome is thought
to be essential for tumor survival. Wang and Quake [70] used the CRISPR/Cas9 system for
antiviral therapy in human cells, specifically targeting the EBV genomes of latent viral
infections. Patient-derived Burkitt’s lymphoma cells with latent EBV infection showed
significant proliferation arrest and decrease in viral load after treatment with specific CRISPR/
Cas9 vector targeting the viral genome. It seems likely that NPC cells would be excellent targets
for transduction in vivo using Sau Cas9/sgRNA-based AAV vectors specific for the EBV
genome.
Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the
central nervous system caused by human polyomavirus JC (JCV) reactivation. JCV replicates
in oligodendrocytes, the myelin-producing cells in the brain. Previously a rare disease seen in
patients with lymphoproliferative and myeloproliferative disorders, PML is now seen more
frequently in HIV-1-positive/AIDS patients and patients undergoing immunomodulatory
therapy due for rheumatological/autoimmune disorders [83]. At this time, there is no cure for
PML, and in most cases, disease progression leads to death within 2 years. The JCV genome
is a small circular double-stranded DNA that includes coding sequences for the viral early
protein, T-antigen, which is critical for directing viral reactivation and lytic infection. Wollebo
et al. [83] applied CRISPR/Cas9 system to introduce mutations in the viral genome to inactivate
the gene encoding T-antigen and inhibit viral replication. Transient or conditional expression
of Cas9 and gRNAs specifically targets the N-terminal region of T-antigen on integrated
genetic and functional studies. The mutation introduced interferes with the expression and
function of the viral protein, suppressing viral replication in vitro [83]. There was no off-target
effect of the JCV-specific CRISPR/Cas9 editing apparatus observed. These studies provide the
first evidence for the employment of a gene editing strategy as a promising tool for the
elimination of the JCV genome and a potential cure for PML.
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HTLV-1, which causes adult T-cell leukemia (ATL) in humans, establishes a lifelong latent
infection. Current therapies are not very effective against HTLV-1-associated disorders. In a
proof-of-concept study, Tanaka et al. [80] developed a targeted endonuclease based on zinc
finger nuclease (ZFN) that specifically recognized a conserved region of HTLV-1 long terminal
repeat (LTR) and introduced it into various HTLV-1-positive human T-cell lines, including
HTLV-1-transformed and ATL-derived cell lines [80]. ZFN disrupted the promoter function
of HTLV-1 LTR and specifically killed HTLV-1-infected cells. The researchers showed the first
evidence of the removal of the proviral genome from HTLV-1-infected cells. The therapeutic
effect of ZFN was confirmed in an in vivo model of ATL. This strategy may form the basis of
a therapy that can eradicate HTLV-1 infection, and similar approaches can be used to target
other malignancy-associated viruses.
Using DNA editing technology to inactivate or mutate DNA virus genomes
Virus Human disease Type Target Cell/animal/
human study
Delivery
method
Reference
Endogenous
retroviruses
(ERV)
Unknown ZFN, CRISPR Pol ATCC CRL-33,
PK15 Pig ATCC
CRL-1573,
human
Transfection Semaan et al.
[69], Mali et al.
[6], Cong et al.
[5]
Epstein–Barr
virus (EBV)
Burkitt’s lymphoma,
NPC, non-Hodgkin’s
lymphomas, oral hairy
leukoplakia,
lymphoproliferative
disease
CRISPR EBNA1 Raji cells,
human
Transfection Wang et al. [70]
Hepatitis B
virus (HBV)
Liver cirrhosis, HCC ZFN Pol, Core,
X
Huh7 cells,
HepAd38 cells
Transfection,
AAV vectors
Cradick et al.
[71], Weber et al.
[72]
TALEN Surface,
Core, Pol
HepG2.2.15,
mouse
Transfection,
HDI
Bloom K et al.
[73]
TALEN Core Huh7 cells Transfection Chen et al. [74]
Lin et al. [75],
Seeger et al. [76],
CRISPR Core, X HepG2/NTCP
cells
Lentiviral
vectors
Kennedy et al.
[77], Dong et al.
[78]
Herpes simplex
type 1 (HSV-1)
Core sores, encephalitis,
pneumonitis, hepatitis
Homing
endonuclease
(HE) HSV1m5
HSV-1
gene
UL19
Primary human
fibroblast
AAV vectors Aubert et al. [79]
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Using DNA editing technology to inactivate or mutate DNA virus genomes
Virus Human disease Type Target Cell/animal/
human study
Delivery
method
Reference
Human T cell
leukemia virus
type 1 (HTLV1)
Adult T cell leukemia
(2–6% of carriers),
tropical spastic
paraparesis, myelopathy,
uveitis, dermatitis
ZFN HTLV-1
LTR
T-cell and ATL-
derived cell
lines
Tanaka et al.
[80]
Human
Papilloma virus
Papilloma, cervical and
other mucosal carcinoma
ZFN HPV-18
ori
293H cells Transfection Mino et al. [81]
CRISPR E6, E7
ORFs
SiHa cells,
mice
Transfection Zhen et al. [82]
Polyomavirus
JC
Progressive multifocal
leukoencephalopathy
CRISPR JCV T-
antigen
gene
HJC-2,
Hamster
Transfection Wollebo et al.
[83]
Table 3. Summary of studies using DNA editing technology to inactivate or mutate DNA virus genomes.
3. Conclusion
The development of effective gene editing technologies has the potential to lead to the global
identification of almost all cellular factors that regulate virus replication in culture, leading to
a wealth of new insights into viral molecular biology and producing numerous potential
targets for antiviral drug development. If such screens can indeed identify cellular factors that
are required for virus replication but entirely dispensable for the health of the adult target
organism, then it might be possible to also treat viral infections, including RNA virus infec‐
tions, via the localized ablation of a cellular gene as described above for direct targeting of
DNA virus genomes. A similar approach has previously been reported using ZFNs to
inactivate the HIV-1 coreceptor CCR5, to prevent the infection of CD4+ T cells, by transduction
of hematopoietic stem cells followed by an analysis of the production of HIV-1-resistant
CD4+ human T cells in engrafted immunodeficient mice [115, 116]. The challenges remain in
applying engineered nucleases in the clinic setting, including immunogenicity of transduced
proteins, with repeated application, delivery of the genes into the correct tissue/cell types, side
effects of off-target mutagenesis, limitations in the design of the nuclease target sites, ethical
issues, including tumorigenicity, undesired integration of nucleases or donor templates, and
the germline transmission of the modified genome. One interesting and novel approach is to
deliver engineered nuclease using modified mRNA, which is nonintegrating and provides a
transient pulse of protein expression, as an alternative to traditional viral vectors. A team of
researchers had recently applied this nuclease-encoding, chemically modified (nec) mRNA to
deliver site-specific nucleases in a transgenic mouse model of SP-B deficiency, resulting in
successful site-specific genome editing in vivo [117, 118]. Although several technical challenges
and uncertainties remain, the promise of using gene correction technology to study and treat
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chronic viral infections is tremendous. Further advances in understanding and improvements
in technology will open the next era of therapy against currently difficult-to-treat viral diseases.
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